Sickle Cell Disease Drugs Market Outlook:
Sickle Cell Disease Drugs Market size was valued at USD 2.9 billion in 2024 and is poised to reach USD 7.8 billion by the end of 2037, expanding at around 12.7% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of sickle cell disease drugs is estimated at USD 3.1 billion.
Food and Drug Administration approval led to market adoption in the global market at a rapid scale, resulting in high market growth of the sickle cell disease drugs. According to the study of the World Health Organization, approximately 290,000 newborns are affected by the disease of sickle cell each year. Intervention of the disease with the help of hydroxyurea and monoclonal antibodies is efficient in overcoming the health risk that has raised the demand for sickle cell disease drugs in the market. Medicare coverage is expanded throughout the world to ensure higher accessibility. For instance, Medicaid coverage is more than 55% of the total treatment cost, which ensures high demand for the sickle cell disease drugs.
API manufacturers that include hydroxyurea are the leading suppliers in the manufacturing of sickle cell disease drugs. More than 75% of the production of FDA-approved drugs is conducted in the U.S. and the EU. Cold chain logistics is necessary to store the drugs for gene therapies, which often complicate the logistics management in low-resource regions. According to the U.S. Bureau of Labour Statistics, the Producer Price Index increased by 7.4% and the Consumer Price Index rose to 9.3%. Research and development within the sickle cell disease drugs elevated through fund allocation of USD 1 billion in 2024, within which over 60% is allocated only for gene-editing technologies.
